Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment

Authors

Ilijana Babic, University of WollongongFollow
Ashleigh Gorak, University of WollongongFollow
Jason Hughes, University of WollongongFollow
Martin Engel, University of WollongongFollow
Dominic Sellers, University of WollongongFollow
Paul Else, University of WollongongFollow
Luisa Lufe, University of WollongongFollow
Anita-Louise Obeid, University of WollongongFollow
Ashleigh Osborne, University of WollongongFollow
P Le Mesurier, University of Wollongong
Nagesh B. Pai, University of WollongongFollow
Xu-Feng Huang, University of WollongongFollow
Katrina Weston-Green, University of WollongongFollow

RIS ID

109146

Publication Details

Babic, I., Gorak, A., Hughes, J., Engel, M., Sellers, D., Else, P., Lufe, L., Obeid, A. L., Osborne, A., Le Mesurier, P., Pai, N., Huang, X. F. & Weston-Green, K. (2016). Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment. International Journal of Neuropsychopharmacology, 19 (Suppl. 1), 55-55.

Abstract

abstract of poster that was presented at the 30th CINP World Congress of Neuropsychopharmacology, 3-5 July, Seoul, Republic of Korea.